TY - JOUR
T1 - Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin
AU - Roncella, Silvio
AU - Ferro, Paola
AU - Franceschini, Maria Cristiana
AU - Bacigalupo, Bartolomeo
AU - Dessanti, Paolo
AU - Sivori, Massimiliano
AU - Carletti, Anna Maria
AU - Fontana, Vincenzo
AU - Canessa, Pier Aldo
AU - Pistillo, Maria Pia
AU - Fedeli, Franco
PY - 2010/6
Y1 - 2010/6
N2 - As was reported that human mammaglobin (hMAM) may be expressed in malignant pleural effusions (PEs), we investigated the relevance of hMAM reverse-transcriptase polymerase chain reaction (RT-PCR) for their diagnosis and determination of primary origin. Two hundred and twenty-eight malignant (132 male, 96 female) and 185 benign (132 male, 53 female) PEs were investigated. Statistical analyses evaluated the diagnostic performance parameters in all PEs and in cytologically negative malignant PEs, the association between hMAM and benign or malignant status by the direct index of correlation [diagnostic odds ratio (DOR)], χ test, and P value (P). In addition, the discriminative diagnostic power of hMAM expression, independently in breast cancer, lung cancer (LC), malignant mesothelioma (MM), and other cancers was evaluated. In the entire patient population, hMAM was detected in 45.6% and 5.4% of malignant and benign PEs, respectively, in the male group in 41.7% and 4.5% and in the female group in 51.0% and 7.5% of malignant and benign PEs, respectively. A statistically significant correlation between hMAM and malignancy was found in the entire population (DOR=14.68, P
AB - As was reported that human mammaglobin (hMAM) may be expressed in malignant pleural effusions (PEs), we investigated the relevance of hMAM reverse-transcriptase polymerase chain reaction (RT-PCR) for their diagnosis and determination of primary origin. Two hundred and twenty-eight malignant (132 male, 96 female) and 185 benign (132 male, 53 female) PEs were investigated. Statistical analyses evaluated the diagnostic performance parameters in all PEs and in cytologically negative malignant PEs, the association between hMAM and benign or malignant status by the direct index of correlation [diagnostic odds ratio (DOR)], χ test, and P value (P). In addition, the discriminative diagnostic power of hMAM expression, independently in breast cancer, lung cancer (LC), malignant mesothelioma (MM), and other cancers was evaluated. In the entire patient population, hMAM was detected in 45.6% and 5.4% of malignant and benign PEs, respectively, in the male group in 41.7% and 4.5% and in the female group in 51.0% and 7.5% of malignant and benign PEs, respectively. A statistically significant correlation between hMAM and malignancy was found in the entire population (DOR=14.68, P
KW - Human mammaglobin
KW - Malignant pleural effusion
KW - Reverse-transcriptase polymerase chain reaction
UR - http://www.scopus.com/inward/record.url?scp=77953166056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953166056&partnerID=8YFLogxK
U2 - 10.1097/PDM.0b013e3181ba6c78
DO - 10.1097/PDM.0b013e3181ba6c78
M3 - Article
C2 - 20502186
AN - SCOPUS:77953166056
VL - 19
SP - 92
EP - 98
JO - Diagnostic Molecular Pathology
JF - Diagnostic Molecular Pathology
SN - 1052-9551
IS - 2
ER -